What We're Reading: Page 122
Industry reads hand-picked by our editors
Mar 21, 2022
Mar 18, 2022
-
The Wall Street Journal
Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date
-
STAT
Lawmakers face off about the future of the FDA’s accelerated approval pathway
-
The Financial Times
AstraZeneca prepared to ditch effort to secure US approval for Covid vaccine
-
The New York Times
‘Stealth’ Omicron Is Stealthy No More: What’s Known About the BA.2 Variant
Mar 17, 2022
Mar 16, 2022
-
STAT
Gilead faces criticism for donations to lawmakers who backed 'Don't Say Gay' bill
-
Undark
The Worrying Murkiness of Institutional Biosafety Committees
-
The Wall Street Journal
Frazier Healthcare Partners Raises $986 Million Biotech Venture Fund
-
Scientific American
Tiny Antennas Made from DNA Light Up Protein Activity
Mar 15, 2022
Mar 14, 2022
-
Reuters
Alzheimer's patient groups pressure U.S. to pay for Biogen drug
-
The Wall Street Journal
Merck’s Covid-19 Pill Heavily Used So Far Despite Concerns
-
Evaluate Vantage
No Ameera glory for Sanofi
-
The New York Times
Novel Malaria Treatment for Children Receives First Approval
Mar 11, 2022
-
The Boston Globe
Scientists say we need universal coronavirus vaccines, but will they arrive in time?
-
Evaluate Vantage
Another strike for biotech: China
-
The Washington Post
Whistleblower alleges bullying, ethical lapses at White House science office
-
MedCity News
MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs
Previous
